Journal for ImmunoTherapy of Cancer · 2023 · 38 citations · 14 references
MedicineOncologyPharmacologyCancer PharmacologyImmunotherapySolid Tumor PharmacotherapyCancer ImmunotherapyImmunotherapy For Solid TumorsTargeted Cancer TherapyTargeted TherapyDose Escalation TherapyDose-escalation DesignsNon-small Cell Lung Cancer ImmunotherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentProgrammed Death-ligand 1 InhibitorsProgrammed Death-ligand 1 TargetingTransforming Growth Factor-beta Signaling
BACKGROUND: NIS793 is a human IgG2 monoclonal antibody that binds to transforming growth factor beta (TGF-β). This first-in-human study investigated NIS793 plus spartalizumab treatment in patients with advanced solid tumors. METHODS: Patients received NIS793 (0.3-1 mg/kg every 3 weeks (Q3W)) monotherapy; following evaluation of two dose levels, dose escalation continued with NIS793 plus spartalizumab (NIS793 0.3-30 mg/kg Q3W and spartalizumab 300 mg Q3W or NIS793 20-30 mg/kg every 2 weeks [Q2W] and spartalizumab 400 mg every 4 weeks (Q4W)). In dose expansion, patients with non-small cell lung cancer (NSCLC) resistant to prior anti-programmed death ligand 1 or patients with microsatellite stable colorectal cancer (MSS-CRC) were treated at the recommended dose for expansion (RDE). RESULTS: Sixty patients were treated in dose escalation, 11 with NIS793 monotherapy and 49 with NIS793 plus spartalizumab, and 60 patients were treated in dose expansion (MSS-CRC: n=40; NSCLC: n=20). No dose-limiting toxicities were observed. The RDE was established as NIS793 30 mg/kg (2100 mg) and spartalizumab 300 mg Q3W. Overall 54 (49.5%) patients experienced ≥1 treatment-related adverse event, most commonly rash (n=16; 13.3%), pruritus (n=10; 8.3%), and fatigue (n=9; 7.5%). Three partial responses were reported: one in renal cell carcinoma (NIS793 30 mg/kg Q2W plus spartalizumab 400 mg Q4W), and two in the MSS-CRC expansion cohort. Biomarker data showed evidence of target engagement through increased TGF-β/NIS793 complexes and depleted active TGF-β in peripheral blood. Gene expression analyses in tumor biopsies demonstrated decreased TGF-β target genes and signatures and increased immune signatures. CONCLUSIONS: In patients with advanced solid tumors, proof of mechanism of NIS793 is supported by evidence of target engagement and TGF-β pathway inhibition. TRIAL REGISTRATION NUMBER: NCT02947165.
14
The consensus molecular subtypes of colorectal cancer
Justin Guinney, Rodrigo Dienstmann, Xin Wang et al. · Nature Medicine · 2015 · 5.3K citations · Full text
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello, Sergio Palomo‐Ponce, Diana Stork et al. · Nature · 2018 · 1.8K citations
Medicine, Cancer Biology, Oncology +14
The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone
Pierrick G.J. Fournier, Patricia Juárez, Guanglong Jiang et al. · Cancer Cell · 2015 · 212 citations · Full text
Medicine, Cancer Biology, Oncology +10